UK Markets open in 1 hr 50 mins

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.4800+0.0800 (+3.33%)
At close: 04:00PM EDT
2.4800 0.00 (0.00%)
After hours: 04:02PM EDT

AC Immune SA

Building B
EPFL Innovation Park
Lausanne 1015
Switzerland
41 21 345 91 21
https://www.acimmune.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Andrea Pfeifer Ph.D.Co-Founder, CEO & Director1.25MN/A1957
Mr. Piergiorgio DonatiChief Technical Operations OfficerN/AN/A1971
Dr. Marie Kosco-VilboisChief Scientific OfficerN/AN/A1958
Mr. Jean-Fabien MoninChief Admin. OfficerN/AN/A1971
Prof. Johannes Rolf Streffer M.D.Chief Medical OfficerN/AN/A1969
Mr. Christopher RobertsInterim CFO & VP of Fin.N/AN/AN/A
Mr. Joshua Drumm Ph.D.Head of Investor RelationsN/AN/AN/A
Mr. Alexandre CaratschGen. CounselN/AN/A1966
Judith MooreGlobal Head of CommunicationsN/AN/AN/A
Mr. Julian SnowVP of U.S. Fin. & Corp. Devel.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Corporate governance

AC Immune SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.